Business
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company’s Board of Directors. “Eric’s decades of financial, transactional and operational experience will make an immediate impact to CERo’s board of directors,” said Chris Ehrlich, Company Chairman and Chief Execut
About this update from Scynexis, Inc.
[{"type":"image","alt":"CERo Therapeutics Holdings, Inc.","displaySize":"","headline":null,"caption":"CERo Therapeutics Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":145,"url":"https://media.zenfs.com/en/globenewswire.com/2ecbccba8b990ea01b1ca363d09f249b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eQxQZ4GdfiIfuokfvdktnQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2ecbccba8b990ea01b1ca363d09f249b","width":300,"height":145}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company’s Board of Directors.","length":314,"tagName":"p"},{"type":"text","content":"“Eric’s decades of financial, transactional and operational experience will make an immediate impact to CERo’s board of directors,” said Chris Ehrlich, Company Chairman and Chief Executive Officer. “Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development.”","length":344,"tagName":"p"},{"type":"text","content":"Mr. Francois is an executive with over 25 years of professional experience in the life science industry. For 18 years he served as a senior banker with Raymond James, Credit Suisse, Lazard, and Cowen, where he provided board-level financial advice on numerous transactions. Formerly, he served as Chief Financial Officer of SCYNEXIS (Nasdaq: SCYX), a publicly traded anti-invectives company, where he was responsible for raising over $300M through equity, debt and non-dilutive sources. He also was an independent director at CervoMed Inc. (formerly known as Diffusion Pharmaceuticals, Inc.) (Nasdaq: CRVO), where he coordinated efforts to merge with EIP Pharma, Inc . Eric earned his M.A in business and marketing from The Sorbonne University, where he also earned his B.A. degree in economics and business administration.","length":835,"tagName":"p"},{"type":"text","content":"“CERo Therapeutics has developed a unique approach to the immunotherapy of cancer, as has been demonstrated across its preclinical work and also in the c...